Beyond Air (NASDAQ:XAIR) Releases Earnings Results, Misses Expectations By $0.20 EPS

Beyond Air (NASDAQ:XAIR) posted its quarterly earnings data on Thursday. The company reported ($11.00) earnings per share for the quarter, missing the consensus estimate of ($10.80) by ($0.20), Zacks reports. The company had revenue of $1.77 million during the quarter, compared to analyst estimates of $1.93 million. Beyond Air had a negative return on equity of 350.00% and a negative net margin of 432.99%.

Here are the key takeaways from Beyond Air’s conference call:

• Second-quarter revenue was $1.8 million, essentially flat year over year and sequentially. Gross margin improved to 13%, marking the third consecutive quarter of positive gross profit, although the company still reported a $7.9 million net loss.
• Beyond Air raised $10 million upfront through financing with potential for up to an additional $20 million from warrant exercises, strengthening its ability to fund Gen 2 LungFit PH production, commercial preparations, and international expansion.
• The company said its Gen 2 LungFit PH submission remains on track for potential FDA approval in the second half of 2026, with audits and pilot builds underway. Management described FDA communication as strong but cautioned that timing remains subject to the agency’s review.
• Commercial momentum is building, including a new national group purchasing agreement that gives Beyond Air access to a substantial portion of U.S. hospitals, a pipeline that management says has doubled over the past five to six months, and distribution partnerships spanning more than 40 countries.
• Management reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million; the 2027 outlook includes potential Gen 2 LungFit PH revenue, while the 2026 forecast excludes any contribution from the new system.

Beyond Air Price Performance

Shares of NASDAQ XAIR traded up $0.87 during midday trading on Thursday, reaching $6.92. The company’s stock had a trading volume of 58,563 shares, compared to its average volume of 163,711. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 3.48. The company has a 50 day moving average price of $7.19 and a 200 day moving average price of $12.44. Beyond Air has a one year low of $5.02 and a one year high of $95.60. The company has a market cap of $4.98 million, a price-to-earnings ratio of -0.08 and a beta of 0.23.

Insiders Place Their Bets

In other Beyond Air news, CEO Robert Scott Goodman bought 34,722 shares of Beyond Air stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $199,998.72. Following the completion of the acquisition, the chief executive officer owned 34,822 shares of the company’s stock, valued at approximately $200,574.72. This represents a 34,722.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.99% of the company’s stock.

Institutional Investors Weigh In On Beyond Air

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Beyond Air by 1.5% during the second quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock worth $144,000 after purchasing an additional 12,598 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Beyond Air in the 3rd quarter valued at $1,753,000. Osaic Holdings Inc. increased its stake in Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Beyond Air in the 3rd quarter worth about $48,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Beyond Air in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $200.00.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.